A retrospective study evaluating the outcomes of high‐dose methylprednisolone pulse therapy for 483 patients with moderate‐to‐severe alopecia areata

Abstract

users (63Á7%). ET (55Á45%) and EPT (51Á5%) users lived in areas with the highest ambient UV exposure more often than 'never ' HT users (47Á0%).We found no association between current ET (HR 1Á36, 95% CI 0Á96-1Á94) or EPT (HR 1Á11, 95% CI 0Á91-1Á36) use and CM risk (Table 1). No significant interaction was observed between naevi and current ET/EPT use overall (P interaction = 0Á075), but among those with naevi, the association with melanoma risk was significantly higher (P = 0Á023) for ET users (HR 1Á63, 95% CI 0Á84-3Á17) than EPT users (HR 0Á64, 95% CI 0Á37-1Á13) (Table 1).In a sensitivity analysis stratified by inclusion before or after results from the Women's Health Initiative were published (i.e. before 2005 or from 2005 onwards), the estimates for current ET and EPT in the two strata were similar. In another sensitivity analysis stratified by healthcare utilization via the proxy measure 'rural/nonrural area of residence', current ET and EPT estimates were similar.Our estimates for ET and EPT are in good agreement with a recent meta-analysis [ET: pooled relative risk (RR) 1Á32, 95% CI 1Á17-1Á49; EPT: RR 1Á12, 95% CI 0Á93-1Á35]. 1 Increasing number of naevi has been associated with higher levels of oestradiol. 8 The indication of a higher CM risk in women with naevi who use ET is in line with this finding.Major strengths of this study include the representative, nationwide population-based prospective design with up to 25 years of follow-up and complete outcome information. The main limitation of the study is the use of self-reported, although validated, exposure information 7 and self-reported covariates. This research letter reports for the first time associations between ET, EPT and melanoma risk stratified by naevi. Unfortunately, the number of exposed cases in the two strata was low and further research is needed.In conclusion, ET and EPT were not associated with CM risk in this nationwide cohort study, and the estimates were in line with recent meta-analyses.

Characterization of rosacea patients in Tohoku area of Japan: Retrospective study of 340 rosacea cases

“…The study was approved by the ethics committee of the Tohoku University Graduate School of Medicine. We retrospectively reviewed medical records of rosacea patients treated between January 2010 and December 2020 in the Department of Dermatology, Tohoku University Hospital, Sendai, Japan, with similar procedures described in the previous reports 11–14 . We identified 431 cases diagnosed as rosacea, rosacea‐like dermatitis, or perioral dermatitis.…”

A Real-World Study of Steroid-Free Monotherapy with Tofacitinib in Severe and Therapy-Recalcitrant Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Cases: A Retrospective Analysis

“…The limitations of steroid regimens and ISAs are enumerated in Supplementary File 1 . [ 14 15 16 17 ]…”

Alopecia areata: What's new in the diagnosis and treatment with JAK inhibitors?

“…30 Another study involving 483 patients with AA treated with methylprednisolone pulse therapy revealed that a history of atopic dermatitis (AD) and AA type affected complete response. 31…”

“…A study of 105 patients with AA treated with methylprednisolone pulse therapy suggested that duration from the onset to therapy was correlated with the duration required for hair regrowth among good responders, whereas “severity,” “relapse,” and “longer duration from the latest onset,” were associated with poorer outcome 30 . Another study involving 483 patients with AA treated with methylprednisolone pulse therapy revealed that a history of atopic dermatitis (AD) and AA type affected complete response 31 …”